tbuckley/cabot-search huggingface dataset:
Single-cell landscape of nuclear configuration and gene expression during stem cell differentiation and X inactivation
Authors: Giancarlo Bonora, Vijay Ramani, Ritambhara Singh, He Fang, Dana L. Jackson, Sanjay Srivatsan, Ruolan Qiu, Choli Lee, Cole Trapnell, Jay Shendure, Zhijun Duan, Xinxian Deng, William S. Noble, Christine M. Disteche
Journal: Genome biology (2021)

Abstract Background Mammalian development is associated with extensive changes in gene expression, chromatin accessibility, and nuclear structure. Here, we follow such changes associated with mouse embryonic stem cell differentiation and X inactivation by integrating, for the first time, allele-specific data from these three modalities obtained by high-throughput single-cell RNA-seq, ATAC-seq, and Hi-C. Results Allele-specific contact decay profiles obtained by single-cell Hi-C clearly show that the inactive X chromosome has a unique profile in differentiated cells that have undergone X inactivation. Loss of this inactive X-specific structure at mitosis is followed by its reappearance during the cell cycle, suggesting a “bookmark” mechanism. Differentiation of embryonic stem cells to follow the onset of X inactivation is associated with changes in contact decay profiles that occur in parallel on both the X chromosomes and autosomes. Single-cell RNA-seq and ATAC-seq show evidence of a delay in female versus male cells, due to the presence of two active X chromosomes at early stages of differentiation. The onset of the inactive X-specific structure in single cells occurs later than gene silencing, consistent with the idea that chromatin compaction is a late event of X inactivation. Single-cell Hi-C highlights evidence of discrete changes in nuclear structure characterized by the acquisition of very long-range contacts throughout the nucleus. Novel computational approaches allow for the effective alignment of single-cell gene expression, chromatin accessibility, and 3D chromosome structure. Conclusions Based on trajectory analyses, three distinct nuclear structure states are detected reflecting discrete and profound simultaneous changes not only to the structure of the X chromosomes, but also to that of autosomes during differentiation. Our study reveals that long-range structural changes to chromosomes appear as discrete events, unlike progressive changes in gene expression and chromatin accessibility.
444P Prevalence of NTRK1/2/3 fusions in dMMR/MSI metastatic colorectal cancer
Authors: M. Svrcek, R. Colle, A. Cayre, L. Mas, P. Bourgoin, R. Cohen, T. André, F. Penault-Llorca, N. Radosevic-Robin
Journal: Annals of Oncology (2021)
Determinants of SARS-CoV-2 entry and replication in airway mucosal tissue and susceptibility in smokers
Authors: Tsuguhisa Nakayama, Ivan T. Lee, Sizun Jiang, Matthias S. Matter, Carol H. Yan, Jonathan B. Overdevest, Chien-Ting Wu, Yury Goltsev, Liang-Chun Shih, Chun-Kang Liao, Bokai Zhu, Yunhao Bai, Peter Lidsky, Yinghong Xiao, David Zarabanda, Angela Yang, Meena Easwaran, Christian M. Schürch, Pauline Chu, Han Chen, Anna K. Stalder, David R. McIlwain, Nicole A. Borchard, Phillip A. Gall, Sachi S. Dholakia, Wei Le, Le Xu, Chih-Jaan Tai, Te-Huei Yeh, Elizabeth Erickson-Direnzo, Jason M. Duran, Kirsten D. Mertz, Peter H. Hwang, Jasmin D. Haslbauer, Peter K. Jackson, Thomas Menter, Raul Andino, Peter D. Canoll, Adam S. DeConde, Zara M. Patel, Alexandar Tzankov, Garry P. Nolan, Jayakar V. Nayak
Journal: Cell Reports Medicine (2021)

Understanding viral tropism is an essential step toward reducing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission, decreasing mortality from coronavirus disease 2019 (COVID-19) and limiting opportunities for mutant strains to arise. Currently, little is known about the extent to which distinct tissue sites in the human head and neck region and proximal respiratory tract selectively permit SARS-CoV-2 infection and replication. In this translational study, we discover key variabilities in expression of angiotensin-converting enzyme 2 (ACE2) and transmembrane serine protease 2 (TMPRSS2), essential SARS-CoV-2 entry factors, among the mucosal tissues of the human proximal airways. We show that SARS-CoV-2 infection is present in all examined head and neck tissues, with a notable tropism for the nasal cavity and tracheal mucosa. Finally, we uncover an association between smoking and higher SARS-CoV-2 viral infection in the human proximal airway, which may explain the increased susceptibility of smokers to developing severe COVID-19. This is at least partially explained by differences in interferon (IFN)-β1 levels between smokers and non-smokers.
1174P Preliminary prediction of EGFR-mutant non-small cell lung cancer outcome using radiomic signature
Authors: J.N. Minatta, C. Mosquera, M. Aineseder, M.A. Mestas Nuñez, D. Deza, L. Lupinacci, L. Basbus, S.E. Benitez, A. Seehaus, D.R. Luna, A.D. Beresñak, F.N. Diaz
Journal: Annals of Oncology (2021)
Reducing behavioral dimensions to study brain–environment interactions
Authors: David Thura
Journal: Behavioral and Brain Sciences (2021)

Abstract Movement vigor provides a window on action valuation. But what is vigor, and how to measure it in the first place? Strikingly, many different co-varying vigor-related metrics can be found in the literature. I believe this is because vigor, just like the neural circuits that determine it, is an integrated, low-dimensional parameter. As such, it can only be roughly estimated.
Machine learning identifies the independent role of dysplasia in the prediction of response to chemotherapy in AML
Authors: Matthieu Duchmann, Orianne Wagner-Ballon, Thomas Boyer, Meyling Cheok, Elise Fournier, Estelle Guerin, Laurène Fenwarth, Bouchra Badaoui, Nicolas Freynet, Emmanuel Benayoun, Daniel Lusina, Isabel Garcia, Claude Gardin, Pierre Fenaux, Cécile Pautas, Bruno Quesnel, Pascal Turlure, Christine Terré, Xavier Thomas, Juliette Lambert, Aline Renneville, Claude Preudhomme, Hervé Dombret, Raphael Itzykson, Thomas Cluzeau
Journal: Leukemia (2021)
825O Ivosidenib in Chinese patients (pts) with relapsed/refractory acute myeloid leukemia (R/R AML) with an IDH1 mutation: Results from a bridging registrational study
Authors: J. Wang, J. Jin, Q. Yin, M. Sun, Y. Liang, C. Chang, J. Zheng, J. Li, C. Ji, J. Zhang, J. Li, Y. Gong, S. Luo, Y. Zhang, R. Chen, Z. Shen, X. Yu, K. Liu, J. Yang
Journal: Annals of Oncology (2021)
184P Prognostic value of geriatric screening tools compared to Balducci criteria on deterioration free survival in elderly patients (pts) with early-stage breast cancer (BC)
Authors: I. Paredero Perez, J. García Sánchez, S. Rubio-Novella, Á. Montes, R.M. LLorente, M. Corbellas Aparicio, M.D. Torregrosa Maicas, I. Maestu Maiques, D. Lorente
Journal: Annals of Oncology (2021)
Phase II study of pembrolizumab in refractory esophageal cancer with correlates of response and survival
Authors: Leonie K de Klerk, Anuj K Patel, Sarah Derks, Eirini Pectasides, Jeremy Augustin, Mohamed Uduman, Nihal Raman, Fahire G Akarca, Nadine J McCleary, James M Cleary, Douglas A Rubinson, Jeffrey W Clark, Bridget Fitzpatrick, Lauren K Brais, Megan E Cavanaugh, Amanda J Rode, Melissa G Jean, Patrick H Lizotte, Matthew J Nazzaro, Mariano Severgnini, Hui Zheng, Charles S Fuchs, Peter C Enzinger, Adam J Bass
Journal: Journal for ImmunoTherapy of Cancer (2021)

Background Immune checkpoint inhibitors have revolutionized cancer treatment, but the benefits in refractory patients with esophageal cancer have been modest. Predictors of response as well as new targets for novel therapeutic combinations are needed. In this phase 2 clinical trial, we tested single-agent pembrolizumab in patients with advanced esophageal cancer, who received at least one prior line of therapy. Methods Pembrolizumab 200 mg every 3 weeks was tested in 49 patients with refractory esophageal cancer: 39 with adenocarcinoma and 10 with esophageal squamous cell carcinoma. Major endpoints were radiological response by Immune-related Response Evaluation Criteria In Solid Tumors and survival. Tumor samples were evaluated for programmed cell death ligand 1 (PD-L1) expression, tumor mutational burden (TMB), and immune contexture by both NanoString mRNA expression analysis and flow cytometry. Peripheral blood mononuclear cells and a panel of circulating chemokines were also analyzed. Results The overall response rate (ORR) was 8% (4 of 49 patients; 95% CI 2.3% to 19.6%). Median overall survival (OS) was 5.8 months (95% CI 4.0 to 9.5). ORR and OS were not associated with histology. For PD-L1-positive patients, ORR was 13.3% (95% CI 1.7% to 40.5%) and median OS was 7.9 months (95% CI 4.7 to 15.5). A trend toward improved OS was observed in seven patients with a TMB ≥10 mut/Mb (p=0.086). Tumors with a PD-L1 Combined Positive Score ≥1 showed enrichment of LAG3 (p=0.005) and IDO1 (p=0.04) gene expression. Baseline levels of circulating CXCL10, interleukin 2 (IL2) receptor α (IL2RA) and IL6 were associated with survival: CXCL10 favorably, (HR 0.37, p=0.002 (progression-free survival); HR 0.55, p=0.018 (OS)); IL2RA and IL6 unfavorably (HR 1.57, p=0.020 for IL6 (OS); HR 2.36, p=0.025 for IL2RA (OS)). Conclusions Pembrolizumab monotherapy was modestly effective in refractory esophageal cancer. Circulating CXCL10 at baseline appeared to be a robust predictor of response. Other T cell exhaustion markers are upregulated in PD-L1-positive patients, suggesting that immunotherapy combinations such as anti-LAG3/programmed cell death protein 1 (PD-1) or anti-IDO1/PD-1 may be of promise in refractory esophageal cancer.
Treatment and outcome of intracranial ependymoma after first relapse in the 2nd AIEOP protocol
Authors: Maura Massimino, Francesco Barretta, Piergiorgio Modena, Pascal Johann, Paolo Ferroli, Manila Antonelli, Lorenza Gandola, Maria Luisa Garrè, Daniele Bertin, Angela Mastronuzzi, Maurizio Mascarin, Lucia Quaglietta, Elisabetta Viscardi, Iacopo Sardi, Antonio Ruggiero, Luna Boschetti, Marzia Giagnacovo, Veronica Biassoni, Elisabetta Schiavello, Luisa Chiapparini, Alessandra Erbetta, Anna Mussano, Carlo Giussani, Rosa Maria Mura, Salvina Barra, Giovanni Scarzello, Giuseppe Scimone, Andrea Carai, Felice Giangaspero, Francesca Romana Buttarelli
Journal: Neuro-Oncology (2021)

More than 40% of patients with intracranial ependymoma need a salvage treatment within 5 years after diagnosis, and no standard treatment is available as yet. We report the outcome after first relapse of 64 patients treated within the 2nd AIEOP protocol.We considered relapse sites and treatments, that is, various combinations of complete/incomplete surgery, if followed by standard or hypofractionated radiotherapy (RT) ± chemotherapy (CT). Molecular analyses were available for 38/64 samples obtained at first diagnosis. Of the 64 cases, 55 were suitable for subsequent analyses.The median follow-up was 147 months after diagnosis, 84 months after first relapse, 5-year EFS/OS were 26.2%/30.8% (median EFS/OS 13/32 months) after relapse. For patients with a local relapse (LR), the 5-year cumulative incidence of second LRs was 51.6%, with a 5-year event-specific probability of being LR-free of 40.0%. Tumor site/grade, need for shunting, age above/below 3 years, molecular subgroup at diagnosis, had no influence on outcomes. Due to variation in the RT dose/fractionation used and the subgroup sizes, it was not possible to assess the impact of the different RT modalities. Multivariable analyses identified completion of surgery, the absence of symptoms at relapse, and female sex as prognostically favorable. Tumors with a 1q gain carried a higher cumulative incidence of dissemination after first relapse.Survival after recurrence was significantly influenced by symptoms and completeness of surgery. Only a homogeneous protocol with well-posed, randomized questions could clarify the numerous issues, orient salvage treatment, and ameliorate prognosis for this group of patients.
1871TiP PLATON – “Platform for Analyzing Targetable Tumor Mutations”: A pilot study
Authors: A. Vogel, D.M. Behringer, S. Bröckling, J. Chater, H-G. Derigs, T. Fietz, T.O. Götze, F. Hartmann, M.P. Lutz, L. Müller, N. Moosmann, J-C. Moulin, J. Potenberg, A. Saborowski, E. Späth-Schwalbe, M.K. Schuler, C. Pauligk, C.B. Westphalen, B. Zäpf, S-E. Al-Batran
Journal: Annals of Oncology (2021)
1719P Peripheral neuropathy and nail dystrophy induced by taxanes: The impact of cryotherapy on the prevention and control of symptoms
Authors: F.R. Salgueiro, C. Costa, J.C. Monteiro, M.R. Pires, A.C. Caetano, I. Ferreira Gomes, C. Caramujo, T. Fraga, M. Mariano, T. Carvalho, P. Madeira, S. Póvoa, A.R. Garcia, I. Pazos, A. Pêgo, S. Broco, I. Domingues, G. Sousa
Journal: Annals of Oncology (2021)
<scp>Up‐Regulated</scp> Interleukin‐10 Induced by <scp>E2F</scp> Transcription Factor 2–<scp>MicroRNA</scp>‐17‐5p Circuitry in Extrafollicular Effector B Cells Contributes to Autoantibody Production in Systemic Lupus Erythematosus
Authors: Lingxiao Xu, Lei Wang, Yumeng Shi, Yun Deng, Jim C. Oates, Diane L. Kamen, Gary S. Gilkeson, Fang Wang, Miaojia Zhang, Wenfeng Tan, Betty P. Tsao
Journal: Arthritis & Rheumatology (2021)

Objective Elevated interleukin‐10 (IL‐10) levels in patients with systemic lupus erythematosus (SLE) have B cell–promoting effects, contributing to autoantibody production and tissue damage. We aimed to characterize up‐regulated IL‐10+ B cell subsets and dysregulated IL10 expression in SLE B cells for new therapeutic options. Methods Proportions of Th10 and IL‐10+ B cell subsets in peripheral blood mononuclear cells (PBMCs) were assessed using flow cytometry. The IL10 3′‐untranslated region (3′‐UTR) dual‐luciferase vector was constructed and cotransfected with small interfering RNA (siRNA), microRNA (miRNA) mimics, or miRNA inhibitors into Raji cells. Transcript levels were quantified using TaqMan assays. Results Culture conditions that induced IL‐10+ Breg cells in healthy controls resulted in expansion of IL‐10+ double‐negative 2 (DN2; IgD−CD27−CD21−CD11c+) B cells in SLE PBMCs. Proportions of IL‐10+ DN2, but not those of IL‐10− DN2, correlated with disease activity and levels of antibodies to double‐stranded DNA (dsDNA) (r = 0.60, P = 0.03 for cohort 1; r = 0.38, P = 0.03 for cohort 2), and were associated with high levels or seropositivity of anti‐Sm ( P = 0.03 for cohort 1; P = 0.01 for cohort 2) and IgG anticardiolipin ( P &lt; 0.01 for cohort 1; P = 0.02 for cohort 2) in SLE patients from 2 cohorts, of mainly African American subjects (cohort 1) and of Asian subjects (cohort 2). Proportions of Th10 (CD45RA−CXCR5−CXCR3+PD‐1 high CD4+) cells correlated with IL‐10+ DN2 frequencies (r = 0.60, P &lt; 0.01 for cohort 2), antinuclear antibody titers (r = 0.52, P = 0.01 for cohort 2), and proteinuria levels (r = 0.72, P &lt; 0.01 for cohort 2) in SLE patients. Screening of predicted IL10 3′‐UTR–targeting miRNAs in SLE B cells identified miRNA‐17‐5p (miR‐17‐5p) and miR‐20a‐5p, with their levels inversely correlated with IL10 (r = −0.47, P &lt; 0.01 for miR‐17‐5p; r = −0.37, P = 0.03 for miR‐20‐5p) and transcription factor E2F2 (r = −0.48, P = 0.04 for miR‐17‐5p; r = −0.45, P = 0.05 for miR‐20‐5p). In Raji cells, knockdown of E2F2 expression resulted in increased levels of miR‐17‐5p and miR‐20a‐5p and decreased IL10 messenger RNA (mRNA) and protein levels, and overexpression and inhibition of miR‐17‐5p down‐regulated and up‐regulated, respectively, IL10 mRNA levels, suggesting regulation of IL10 expression by an E2F2 ‐miR‐17‐5p loop. Conclusion IL‐10 promotes extrafollicular autoimmune responses in patients with active SLE, which might be dampened by targeting the E2F2 –miR‐17‐5p circuitry.
LBA23 EPIK-P1: Retrospective chart review study of patients (pts) with PIK3CA-related Overgrowth Spectrum (PROS) who have received alpelisib (ALP) as part of a compassionate use programme
Authors: G. Canaud, J.C. López Gutiérrez, A. Irvine, N. Ankrah, A. Papadimitriou, A. Ridolfi, D.M. Adams
Journal: Annals of Oncology (2021)
266P MEN1611, a PI3K inhibitor, combined with trastuzumab (T) ± fulvestrant (F) for HER2+/PIK3CA mutant (mut) advanced or metastatic (a/m) breast cancer (BC): Safety and efficacy results from the ongoing phase Ib study (B-PRECISE-01)
Authors: M. Piccart, M. Ruiz Borrego, H-T. Arkenau, S.I. Escrivá-de-Romaní, S.J. Howell, A. Hennequin, B. Jimenez-Rodriguez, G. Del Conte, M. Simonelli, M. Palleschi, F. Duhoux, B. Doger De Speville Uribe, G. Curigliano, S. Waters, P.G. Aftimos, H. Wildiers, D. Tosi, F. Amair-Pinedo, A.U.E. Pellacani, D.O. Laurent
Journal: Annals of Oncology (2021)
A Bioreactor Simulating Pulse-Pressure Mediated Circumferential Stretch Stimulates Hematopoietic Stem Cell Formation
Authors: Giorgia Scapin, Jennifer Cillis, Liisa Kanninen, Taylor Patch, Vanessa Lundin, Elliott J. Hagedorn, Vikas Trivedi, Heidi Andeson, Leonard I. Zon, George Q. Daley, Dhvanit I Shah
Journal: Blood (2017)
1196P Pre-existing and acquired mechanisms of resistance to lorlatinib in previously treated patients (pts) with ALK+ advanced non-small cell lung cancer (NSCLC)
Authors: B.J. Solomon, J-F. Martini, A. Bearz, E.H. Tan, R. Soo, B. Besse, T.M. Bauer, D. Shepard, F. Toffalorio, A. Abbattista, E. Felip, A.T. Shaw, S. Viteri, D.R. Camidge, T. Seto, S-H.I. Ou
Journal: Annals of Oncology (2021)
Elevated T cell repertoire diversity is associated with progression of lung squamous cell premalignant lesions
Authors: Asaf Maoz, Carter Merenstein, Yusuke Koga, Austin Potter, Adam C Gower, Gang Liu, Sherry Zhang, Hanqiao Liu, Christopher Stevenson, Avrum Spira, Mary E Reid, Joshua D Campbell, Sarah A Mazzilli, Marc E Lenburg, Jennifer Beane
Journal: Journal for ImmunoTherapy of Cancer (2021)

Objective The immune response to invasive carcinoma has been the focus of published work, but little is known about the adaptive immune response to bronchial premalignant lesions (PMLs), precursors of lung squamous cell carcinoma. This study was designed to characterize the T cell receptor (TCR) repertoire in PMLs and its association with clinical, pathological, and molecular features. Methods Endobronchial biopsies (n=295) and brushings (n=137) from high-risk subjects (n=50), undergoing lung cancer screening at approximately 1-year intervals via autofluorescence bronchoscopy and CT, were profiled by RNA-seq. We applied the TCR Repertoire Utilities for Solid Tissue/Tumor tool to the RNA-seq data to identify TCR CDR3 sequences across all samples. In the biopsies, we measured the correlation of TCR diversity with previously derived immune-associated PML transcriptional signatures and PML outcome. We also quantified the spatial and temporal distribution of shared and clonally expanded TCRs. Using the biopsies and brushes, the ratio of private (ie, found in one patient only) and public (ie, found in two or more patients) TCRs was quantified, and the CDR3 sequences were compared with those found in curated databases with known antigen specificities. Results We detected 39,303 unique TCR sequences across all samples. In PML biopsies, TCR diversity was negatively associated with a transcriptional signature of T cell mediated immune activation (p=4e-4) associated with PML outcome. Additionally, in lesions of the proliferative molecular subtype, TCR diversity was decreased in regressive versus progressive/persistent PMLs (p=0.045). Within each patient, TCRs were more likely to be shared between biopsies sampled at the same timepoint than biopsies sampled at the same anatomic location at different times. Clonally expanded TCRs, within a biopsied lesion, were more likely to be expanded at future time points than non-expanded clones. The majority of TCR sequences were found in a single sample, with only 3396 (8.6%) found in more than one sample and 1057 (2.7%) found in two or more patients (ie, public); however, when compared with a public database of CDR3 sequences, 4543 (11.6%) of TCRs were identified as public. TCRs with known antigen specificities were enriched among public TCRs (p&lt;0.001). Conclusions Decreased TCR diversity may reflect nascent immune responses that contribute to PML elimination. Further studies are needed to explore the potential for immunoprevention of PMLs.
Characterization of the Genomic and Immunologic Diversity of Malignant Brain Tumors through Multisector Analysis
Authors: Maximilian O. Schaettler, Megan M. Richters, Anthony Z. Wang, Zachary L. Skidmore, Bryan Fisk, Katherine E. Miller, Tammi L. Vickery, Albert H. Kim, Michael R. Chicoine, Joshua W. Osbun, Eric C. Leuthardt, Joshua L. Dowling, Gregory J. Zipfel, Ralph G. Dacey, Hsiang-Chih Lu, Tanner M. Johanns, Obi L. Griffith, Elaine R. Mardis, Malachi Griffith, Gavin P. Dunn
Journal: Cancer Discovery (2021)

Abstract Despite some success in secondary brain metastases, targeted or immune-based therapies have shown limited efficacy against primary brain malignancies such as glioblastoma (GBM). Although the intratumoral heterogeneity of GBM is implicated in treatment resistance, it remains unclear whether this diversity is observed within brain metastases and to what extent cancer cell–intrinsic heterogeneity sculpts the local immune microenvironment. Here, we profiled the immunogenomic state of 93 spatially distinct regions from 30 malignant brain tumors through whole-exome, RNA, and T-cell receptor sequencing. Our analyses identified differences between primary and secondary malignancies, with gliomas displaying more spatial heterogeneity at the genomic and neoantigen levels. In addition, this spatial diversity was recapitulated in the distribution of T-cell clones in which some gliomas harbored highly expanded but spatially restricted clonotypes. This study defines the immunogenomic landscape across a cohort of malignant brain tumors and contains implications for the design of targeted and immune-based therapies against intracranial malignancies. Significance: This study describes the impact of spatial heterogeneity on genomic and immunologic characteristics of gliomas and brain metastases. The results suggest that gliomas harbor significantly greater intratumoral heterogeneity of genomic alterations, neoantigens, and T-cell clones than brain metastases, indicating the importance of multisector analysis for clinical or translational studies. This article is highlighted in the In This Issue feature, p. 1
Unraveling an Innate Mechanism of Pathological Mineralization‐Regulated Inflammation by a Nanobiomimetic System
Authors: Dongyang Wang, Xiaomeng Wang, Lei Huang, Ziyi Pan, Kexuan Liu, Beibei Du, Ying Xue, Bei Li, Yuan Zhang, Huan Wang, Daowei Li, Hongchen Sun
Journal: Advanced Healthcare Materials (2021)

Abstract Pathological mineralization (PTM) often occurs under inflammation and affects the prognosis of diseases, such as atherosclerosis and cancers. However, how the PTM impacts inflammation has not been well explored. Herein, poly lactic‐ co ‐glycolic acid (PLGA)/gelatin/hydroxyapatite (HA) electrospun nanofibers are rationally designed as an ideal PTM microenvironment biomimetic system for unraveling the role of PTM on inflammation. The results demonstrate that the inflammatory response decreases continuously during the process of mineralization. When mature macromineralization forms, the inflammation almost completely disappears. Mechanistically, the PTM formation is mediated by matrix proteins, local high calcium, and cell debris (nuclei), or actively regulated by the lysosomal/plasma membrane components secreted by macrophages. These inflammatory inducible factors (calcium, cell debris, etc.) can be “buried” through PTM process, resulting in reduced immune responses. Overall, the present study demonstrates that PTM is an innate mechanism of inflammation subsidence, providing valuable insight into understanding the action of mineralization on inflammation.
682P Real-world utilization and outcomes of immune-based combination therapies or tyrosine kinase inhibitors (TKIs) for advanced renal cell carcinoma (aRCC)
Authors: D. Geynisman, J.K. Kish, A. Falkenstein, V. Del Tejo, B. Stwalley, S. Huo, A. Balanean, B.A. Feinberg
Journal: Annals of Oncology (2021)